Off-Label Use OK When Not Promoted, GSK Exec Says

Law360, New York (May 4, 2011, 7:46 PM EDT) -- Prescribing Wellbutrin for off-label uses is fine, GlaxoSmithKline PLC just can't promote the antidepressant for such uses, a company executive testified Wednesday in the Maryland trial of a former GSK attorney who allegedly obstructed a probe into the drug's marketing.

“Off-label uses, especially in the depression area, aren’t uncommon,” James Millar, GSK vice president of strategic pricing, contracting and marketing, told a jury in the trial of the drugmaker's ex-associate general counsel, Lauren Stevens.

“That’s where clinical judgment comes into play. While you may use Wellbutrin...
To view the full article, register now.

Related

Sections

Case Information

Case Title

USA v. Stevens


Case Number

8:10-cr-00694

Court

Maryland

Nature of Suit

Date Filed

November 8, 2010

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.